CDC suggests shortened isolation after positive COVID-19 antigen test
Isolation is recommended during acute infection with SARS-CoV-2, the virus that causes COVID-19, but the duration of infectiousness varies among individual persons, according to the Centers for Disease Control and Prevention (CDC).
Rapid antigen test results have been correlated with detection of viable virus and might inform isolation guidance, but data are limited for the recently emerged SARS-CoV-2 B.1.1.529 (Omicron) variant.
On January 5, 2022, the Yukon-Kuskokwim Health Corporation (YKHC) recommended that persons with SARS-CoV-2 infection isolate for 10 days after symptom onset (or, for asymptomatic persons, 10 days after a positive nucleic acid amplification or antigen test result). However, isolation could end after 5–9 days if symptoms were resolving or absent, fever was absent for ≥24 hours without fever-reducing medications, and an Abbott BinaxNOW COVID-19 Ag rapid antigen test result was negative.
Antigen test results and associated individual characteristics were analyzed among 3,502 infections reported to YKHC during January 1–February 9, 2022. After 5–9 days, 396 of 729 persons evaluated (54.3%) had a positive antigen test result, with a declining percentage positive over time. In a multivariable model, a positive antigen test result was more likely after 5 days compared with 9 days or after symptomatic infection, and less likely after previous infection, receipt of a primary COVID-19 vaccination series, or after both previous infection and receipt of a primary COVID-19 vaccination series. Antigen tests might be a useful tool to guide recommendations for isolation after SARS-CoV-2 infection. During the 10 days after infection, persons might be infectious to others and are recommended to wear a well-fitting mask when around others, even if ending isolation after 5 days.
YKHC provides healthcare and public health services to approximately 27,000 persons in an area of southwest Alaska that includes 50 remote communities; high rates of COVID-19 have been reported in this region. On January 5, 2022, after rapidly increasing incidence of SARS-CoV-2 infections associated with introduction of the Omicron variant, YKHC recommended an isolation policy incorporating the use of SARS-CoV-2 antigen tests. All persons with a positive SARS-CoV-2 antigen or nucleic acid amplification test (NAAT) result were eligible to receive a follow-up BinaxNOW SARS-CoV-2 antigen test 5–9 days after symptom onset (or, in asymptomatic persons, after the first positive test result) if the person reported no symptoms or resolving symptoms, and no fever for ≥24 hours without fever-reducing medications. Persons were recommended to isolate for 10 days but could end isolation after 5–9 days if the follow-up antigen test was negative; all persons were advised to wear a well-fitting mask around others and to avoid close contact with persons at elevated risk for severe COVID-19, until the end of the 10-day period.
Persons with a positive SARS-CoV-2 NAAT or antigen test result were interviewed by a public health or clinic staff member after notification to YKHC, and at the time of a follow-up antigen test, if performed after the initial interview. Information collected included age, sex, whether the person was of the American Indian or Alaska Native race, and whether any symptoms were reported during follow-up. Persons were considered vaccinated if ≥14 days had elapsed since completion of a primary COVID-19 vaccination series and were considered to have received a booster dose if ≥7 days had elapsed after receipt of their booster dose. Previous infection was defined as a previous positive NAAT or antigen test result >90 days before the current infection episode; vaccination and previous infection status were assessed from electronic health records. Follow-up antigen testing was performed by YKHC staff members at a local health facility using the BinaxNOW antigen test; results of the first follow-up antigen test were recorded in the electronic health record.
Positive results of the first follow-up antigen test were evaluated by demographic characteristics, symptom status, previous infection, vaccination status, and number of days since symptom onset or a positive test result. Multivariable logistic regression models were used to identify factors independently associated with a positive follow-up antigen test result, adjusted for age group, previous infection, vaccination status, presence of symptoms, and number of days since symptom onset or the initial positive test result. Statistical analyses were conducted using SAS, using a two-sided significance threshold of p<0.05; univariate comparisons were made using the chi-square test. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.
During January 1–February 9, 2022, a total of 3,502 persons with SARS-CoV-2 infection were reported to YKHC, including 3,266 (93.3%) in whom symptom onset or the initial positive test result had occurred 5–9 days earlier. Among these persons, 729 (22.3%) received a follow-up BinaxNOW antigen test 5–9 days after symptom onset or, among asymptomatic persons, after the first positive test result. The median age was 30 years, 380 (52.1%) were female, and 666 (91.4%) were of the American Indian or Alaska Native race. By the day of the initial positive test, 541 (74.2%) had completed a primary COVID-19 vaccination series ≥14 days earlier, including 215 (39.7%) who had also received a booster dose; 21 (2.9%) persons were partially vaccinated, and 167 (22.9%) were unvaccinated. Previous infection was documented in 145 (19.9%) persons, including 108 who had also completed a primary COVID-19 vaccination series; among persons with a previous infection, a median of 418 and to have received a primary COVID-19 vaccine series (74.2% versus 59.9%; p<0.001), although other characteristics were similar.
Persons are estimated to be most infectious approximately 4 days after SARS-CoV-2 infection, and SARS-CoV-2 virus generally can be cultured up to 10 days after symptom onset. Rapid antigen test results have previously been shown to correlate with real-time reverse transcription–polymerase chain reaction cycle threshold values, and with detection of viable virus, for several days after infection. Among persons in this study with symptomatic infection, 64% received a positive antigen test result during the 5–9 days after symptom onset. However, a positive antigen test result does not necessarily mean that a person is infectious; similarly, a negative test result does not necessarily mean that a person is not infectious. Nonetheless, a positive or negative antigen test might be a useful proxy for the risk for being infectious. Therefore, lower prevalence of positive test results over time and after asymptomatic infections might reflect lower infectiousness. However, even if a person is infectious after an initial diagnosis, the risk for transmission to others depends on other important factors, including the duration and proximity of contact with others, and proper use of a well-fitting mask. Following CDC recommendations, YKHC advised continued mask use for 10 days after symptom onset even if a person met the criteria for ending isolation after 5 days. The high percentage of positive antigen test results during the 5–9 days after symptom onset reinforces the importance of correct and consistent mask use during this period.
The findings in this report are subject to at least six limitations. First, only one follow-up antigen test was included in the analysis for each person; data were cross-sectional rather than longitudinal. However, the multivariable model accounted for changes in reported characteristics over time. Second, the timing of acquisition of asymptomatic infections was unknown, limiting interpretation of changes in positivity over time in this group. Third, information is still accruing on the correlation between antigen tests and virus culture over time. Correlation might vary between some tests or after introduction of the Omicron variant, although initial viral titers appear to be similar between Omicron and B.1.617.2 (Delta) variants. Fourth, approximately 22% of persons who were 5–9 days after illness onset or an initial positive test result opted to have a follow-up antigen test, introducing potential selection bias. The sample was limited to persons whose symptoms were already resolving and might not be representative of all reported cases in other ways. Fifth, behavioral bias associated with the threshold for testing initially or during follow-up could possibly affect comparisons between individual characteristics. Finally, the results might be confounded by unmeasured factors.
Approximately 50% of antigen tests were positive 5–9 days after infection, but the percentage of positive results declined during this period and was lower after asymptomatic infection, after previous infection, and in persons who have completed a primary COVID-19 vaccine series. During the 10 days after infection, persons might be infectious to others and are recommended to wear a well-fitting mask when around others, and to avoid contact with those at elevated risk for severe disease, even if ending isolation after 5 days. Antigen tests might be a useful tool to guide recommendations for isolation after SARS-CoV-2 infection.
